StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Piper Jaffray Cuts Bristol-Myers (BMY) PT, Raises Merck's (MRK) Following BMY's CM-026 Failure
August 8, 2016 6:37 AM
Piper Jaffray analyst Richard Purkiss lowered his price target on Neutral-rated Bristol-Myers Squibb Co. (NYSE: BMY) to $65.00 (from $69.00) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Credit Suisse Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
August 8, 2016 6:20 AM
Bristol-Myers Squibb's (BMY) 'Disappointing' Opdivo Data in NSCLC has No Impact on Ratings - Moody's
August 5, 2016 3:48 PM
Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight
August 5, 2016 1:24 PM
Deutsche Bank Comments on Bristol-Myers Squibb (BMY) Opdivo News; Analyst Says Merck (MRK) Not Guaranteed to be Alone in Front-Line Setting
August 5, 2016 11:25 AM
Bristol-Myers (BMY) Opdivo Trial Miss a 'Seismic Event', BMO Capital Says (MRK)
August 5, 2016 10:00 AM
Merck (MRK) Surges After Bristol-Myers Squibb's (BMY) CheckMate -026 Trial Fails
August 5, 2016 8:24 AM
Bristol-Myers Squibb (BMY) Says CheckMate -026 Trial for Opdivo Missed Primary Endpoint
August 5, 2016 8:21 AM
